Skip to main content
OpenTrials
Completed

NCT Number: NCT02942524

Checklist Tool in Engaging Patients in the Discharge Planning Process

This clinical trial studies how well a checklist tool works in engaging patients in the discharge planning process. Engaging patients in the discharge process may increase participation in the discharge process and improve discharge outcomes, understanding of care after hospitalization, and decrease complications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hospitalization Malignant Neoplasm Neoplasms Transitional Care Planning

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

About this study

PRIMARY OBJECTIVES:

I. Measure the impact on discharge and transition satisfaction of utilizing questions from the Consumer Assessment of Healthcare Providers and Systems (CHAPS) patient satisfaction survey.

II. Measure the impact of the Tool to Engage Patients in Discharge (TEPID) on patient's Readiness for Hospital Discharge and Problems After Discharge Questionnaire-English (PADQ-E) results.

III. Measure the impact on decreasing healthcare utilization measures: readmission rates within 30 days from hospital discharge, hospital length of stay of admission in hospital, and emergency department visits within 30 days of hospital discharge.

OUTLINE:

Patients complete the TEPID checklist of items during hospital stay.

After completion of the study, patients are followed up for 35 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients fluent in English, conscious, coherent, and alert or have an adult caregiver present that is fluent in English will be identified for the TEPID research project

Exclusion criteria

  • Patients discharged to another inpatient facility (hospice, skilled nursing facility, long term acute care hospital [LTACH], or acute rehab) or patients discharged home with hospice will be excluded
  • Any patients that are transferred to another unit prior to discharge will be excluded

Treatment and study plan

Communication intervention

Other

Complete TEPID

Questionnaire Administration

Other

Ancillary studies

Survey Administration

Other

Ancillary studies

Primary outcomes

  1. Average score from the PADQ-E

    Time frame: Up to 12 months

    A simple analysis of variance (ANOVA) model with floor as a fixed blocking factor treatment (TEPID or no TEPID) as a fixed factor. Unit appears in the model as a nested factor within treatment, and statistical tests will be adjusted for this nesting structure. The main test of interest in each model is the overall effect of treatment, which quantifies the effect of TEPID on the average score for the response. P-values below 0.05 for this effect will be considered statistically significant.

  2. Average score from the Readiness for Hospital Discharge Scale

    Time frame: Up to 12 months

    A simple ANOVA model with floor as a fixed blocking factor treatment (TEPID or no TEPID) as a fixed factor. Unit appears in the model as a nested factor within treatment, and statistical tests will be adjusted for this nesting structure. The main test of interest in each model is the overall effect of treatment, which quantifies the effect of TEPID on the average score for the response. P-values below 0.05 for this effect will be considered statistically significant.

  3. Emergency department visits

    Time frame: Up to 12 months

    A generalized linear model will be used for the binary responses (readmission and ED visit).

  4. Patient satisfaction as measured by the Press Ganey Consumer Assessment of Healthcare Providers and Systems Survey

    Time frame: Up to 12 months

    A simple ANOVA model with floor as a fixed blocking factor treatment (TEPID or no TEPID) as a fixed factor. Unit appears in the model as a nested factor within treatment, and statistical tests will be adjusted for this nesting structure. The main test of interest in each model is the overall effect of treatment, which quantifies the effect of TEPID on the average score for the response. P-values below 0.05 for this effect will be considered statistically significant.

  5. Readmission rates

    Time frame: Up to 12 months

    A generalized linear model will be used for the binary responses (readmission and ED visit).

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Registry information

Official study title

Tool to Engage Patients in Discharge (TEPID)

Acronym: TEPID

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Oct 24, 2016
Registry last updated
Jul 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.